Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. (Q30425705)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

main subject

Clostridium difficile

0 references

fidaxomicin

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Brian J Angus

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

2

A Sarah Walker

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

13

Timothy E A Peto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1

Derrick W Crook

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

10

Bernadette C Young

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

9

Nicole E Stoesser

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Yin Kean

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Karl Weiss

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Mark A Miller

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Roberto Esposito

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Thomas J Louie

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Sherwood L Gorbach

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Study 003/004 Teams

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

English

0 references

publication date

1 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

Clinical Infectious Diseases

6 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

55 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

S93-103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

Fidaxomicin versus vancomycin for Clostridium difficile infection

6 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

Clinical risk factors for severe Clostridium difficile-associated disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

Designing and interpreting HIV noninferiority trials in naive and experienced patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

An epidemic, toxin gene-variant strain of Clostridium difficile

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

In vitro activity of OPT-80 against Clostridium difficile

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388031

A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.

20 June 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS499

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS499

Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS499

Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS499

A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS499

The problem of subgroup analyses: an example from a trial on ruptured intracranial aneurysms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS499

Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS499

Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS499

Health Care–AssociatedClostridium difficileInfection in Canada: Patient Age and Infecting Strain Type Are Highly Predictive of Severe Outcome and Mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS499

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22752871

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/CID/CIS499

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22752871%20AND%20SRC:MED&resulttype=core&format=json